Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Dichloroacetate [CDA] . sodium salt [2156-56-1]

Research Use Only
AG-CR1-3684
AdipoGen Life Sciences
CAS Number2156-56-1
Product group Chemicals
Estimated Purity>98%
Molecular Weight127.9 . 23.0
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Dichloroacetate [CDA] . sodium salt
  • Delivery Days Customer
    10
  • CAS Number
    2156-56-1
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C2HCl2O2 . Na
  • Molecular Weight
    127.9 . 23.0
  • Scientific Description
    Chemical. CAS: 2156-56-1. Formula: C2HCl2O2 . Na. MW: 127.9 . 23.0. Synthetic. Analog of acetic acid. Mitochondrial pyruvate dehydrogenase kinase (PDK) inhibitor, consequently activating pyruvate dehydrogenase (PDH). Decreases glycolysis. Shifts pyruvate metabolism from glycolysis and lactate production to glucose oxidation in the mitochondria. Antitumor agent. Decreases tumor growth in vitro and in vivo. Induces mitochondrial-dependent apoptosis. Useful agent for immunometabolism research. Glucose entering the cell is metabolized by glycolysis to pyruvate. Most of the pyruvate in non-cancerous cells enters the mitochondria under aerobic conditions and a small fraction is metabolized to lactate. PDH in mitochondria converts pyruvate into acetyl-CoA, which enters the TCA cycle. In cancer cells, the oxidative (mitochondrial) pathway of glucose utilization is suppressed and most of the pyruvate is converted into lactate (Warburg effect). The relative activities of LDH and PDH therefore determine the fate of pyruvate. PDK inhibits PDH through phosphorylation and regulates its activities, resulting in suppression of the TCA cycle and mitochondrial respiration. This renders PDK a promising target for the treatment of various cancers. - Mitochondrial pyruvate dehydrogenase kinase (PDK) inhibitor, consequently activating pyruvate dehydrogenase (PDH). Decreases glycolysis. Shifts pyruvate metabolism from glycolysis and lactate production to glucose oxidation in the mitochondria. Antitumor agent. Decreases tumor growth in vitro and in vivo. Induces mitochondrial-dependent apoptosis. Useful agent for immunometabolism research. Glucose entering the cell is metabolized by glycolysis to pyruvate. Most of the pyruvate in non-cancerous cells enters the mitochondria under aerobic conditions and a small fraction is metabolized to lactate. PDH in mitochondria converts pyruvate into acetyl-CoA, which enters the TCA cycle. In cancer cells, the oxidative (mitochondrial) pathway of glucose utilization is suppressed and most of the pyruvate is converted into lactate (Warburg effect). The relative activities of LDH and PDH therefore determine the fate of pyruvate. PDK inhibits PDH through phosphorylation and regulates its activities, resulting in suppression of the TCA cycle and mitochondrial respiration. This renders PDK a promising target for the treatment of various cancers.
  • SMILES
    ClC(Cl)C([O-])=O.[Na+]
  • Storage Instruction
    2°C to 8°C,RT
  • UNSPSC
    12352200